N@N

Proteonomix, Inc: Proteonomix, Inc. (PROT) Announces the Effectiveness of the Appointment of Steven Byle to Its Board of Direct

_{//health-fitness.news-articles.net/content/2009/ .. tment-of-steven-byle-to-its-board-of-direct.html}
^{Published in Health and Fitness on Friday, January 16th 2009 at 9:40 GMT, Last Modified on 2009-01-16 09:41:08 by Market Wire}  

MOUNTAINSIDE, NJ--(Marketwire - January 16, 2009) - Proteonomix, Inc. (PINKSHEETS: [ PROT ]) announces that Steven Byle has commenced his tenure on its board of directors.

Mr. Byle stated: "It is a great pleasure to join the board of directors of [ Proteonomix, ] a company which has developed in a relatively short period of time and, without major capital investment, first class technologies which fill the gaps in present stem cell research and development. I believe that its expansion technology which enables the replication of stem cells through many generations without substantial differentiation can provide the quantity of stem cells needed for therapeutic use in diabetes, cardiac and cancer. As an intellectual property attorney, I am gratified at the patent applications of technologies developed or jointly developed by the [ Company's President, Michael Cohen, ] and the assignment to the Company of all patent rights."

In addition, the Company's cosmoceutical to be marketed by its subsidiary, Proteoderm, Inc., is unique and can benefit millions of women by improving their appearance without the risks of Botox, injections or surgery. "As a fluent speaker of Chinese, having lived and worked extensively in Asia and SE Asia over two decades, as well as a successful international entrepreneur, I can assist with the joint ventures of Proteoderm in Pacific Rim countries."

[ Michael Cohen, CEO of Proteonomix ], stated: "I am delighted at the experience and skills which Steven can bring to our board of directors and look forward to working with him as our company moves forward to market."

About Proteonomix, Inc.

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Its research and development program has demonstrated results with more than ten patent applications and multiple products ready to enter their respective markets. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, Inc. has developed a line of anti-aging cosmetics. For more information, please visit [ www.proteonomix.com ] or [ www.proteoderm.com ] and [ www.pinksheets.com ].

"Safe Harbor"

Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto may not occur.